Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00646204 · ClinicalTrials.gov registry record · Phase 4
Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease
A Phase 4 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT00646204 is a Phase 4 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 40 participants.
The verdict
NCT00646204, a Phase 4 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
To evaluate the effects of Memantine on non-motor symptoms in patients with Parkinson's disease. Parkinson's disease (PD) affects about one million people in the United States. It is a common neurological condition that is clinically defined by rigidity (muscle stiffness), bradykinesia (slowness of movement) and tremor. Parkinson's Disease , however, reveals numerous non-motor symptoms that have been underemphasized. Problematic symptoms include varying degrees of dementia, psychosis, diminished assertiveness and confidence, general fatigue, excessive daytime sleepiness, problems with blood pressure, sweating, and bladder, and a common yet difficult to define sense of "not feeling well".
Interventions
- DRUG placebo
- DRUG Memantine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-04 |
| Est. Completion | 2009-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00646204
The ClinicalTrials.gov registry entry for NCT00646204 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00646204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00646204 about?
NCT00646204 is a clinical study titled "Namenda (Memantine) for Non-motor Symptoms in Parkinson's Disease". To evaluate the effects of Memantine on non-motor symptoms in patients with Parkinson's disease. Parkinson's disease (PD) affects about one million people in the United States. It is a common neurological condition that is clinically defined by rigidity (muscle stiffness), bradykinesia (slowness of...
What is the current status of trial NCT00646204?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2006-04. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00646204?
The interventions under investigation include: placebo (DRUG), Memantine (DRUG).
Who is sponsoring clinical trial NCT00646204?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.